

NCIC CLINICAL TRIALS GROUP

**INVESTIGATIONAL NEW DRUG COMMITTEE**

OPEN IND COMMITTEE AGENDA

Friday April 30 2010; 13.30 – 16.30  
Fairmont Queen Elizabeth Hotel, Montreal  
Room: Jolliet  
Chair: Kim Chi

---

- 1.30 p.m. Welcome from the Chair
- 1:35 pm **FINAL TRIAL REPORTS (8-9 MIN EACH)**
- |         |  |                           |
|---------|--|---------------------------|
| IND.179 | Phase I trial of CCI 779, paclitaxel, carboplatin  | Christian Kollmannsberger |
| IND.186 | Phase I/II trial of sorafenib + LD AraC in AML/MDS | David MacDonald           |
| IND.188 | Phase I trial of SB939 in solid tumours            | Sebastien Hotte           |
| IND.189 | Phase II trial of IL21 in metastatic melanoma      | Teresa Petrella           |
- 2:15 p.m. GUEST SPEAKER: **CANCER STEM CELLS: TARGETS AND NEW AGENTS** Percy Ivy, CTEP
- 2:45 pm BREAK – 15 minutes –
- 3:00 pm GUEST SPEAKER: **NEW AGENTS AT ASTRAZENECA** Jeffrey Sklonick, AstraZeneca
- 3:30 pm NEW TRIALS
- |   |  |                            |
|---|--|----------------------------|
| Met inhibitor –foretinib (15 min)                         |  |                            |
| Background on foretinib                                   |  | Rachel Goodwin             |
| IND.196 (lung)  |  | Natasha Leighl             |
| IND. 197 (TN breast), 198 (HER2+ breast)                  |  | Danny Rayson, Stephen Chia |
| NEW Pediatric IND Program (10 min)                        |  | Sylvain Baruchel           |
| IND.203   |  |                            |
| Aurora Kinase Inhibitor AT9283 (15 min)                   |  |                            |
| Background on AT9283                                      |  | Rahima Jamal               |
| IND.181 Phase I trial of AT9283 (aurora kinase inhibitor) |  | Susan Dent                 |
| IND.191 Phase II trial in myeloma                         |  | Rahima Jamal               |
- 4:20 pm Other New / Planned Studies, Report from Closed IND meeting EE, LS
- 4:30 p.m. Adjourn